The Risks of Exuberant Immune Responses
In healthy individuals, immune responses tend to operate in a well-balanced manner. Fever does not escalate excessively, and localized inflammation remains contained, targeting only foreign substances at the site of infection. However, this equilibrium can sometimes falter. When the immune system overreacts, the very processes designed to protect the body can spiral out of control, leading to severe acute or chronic inflammation of organs and the risk of autoimmune diseases such as rheumatism or multiple sclerosis.
Interleukin-1 and Its Receptor Antagonist: A Focus of Research
Researchers at the José Carreras Center for Immunotherapy at the University of Saarland, led by Lorenz Thurner, have long been exploring these intricate immune processes. One key signaling molecule in their studies is Interleukin-1 (IL-1), which triggers inflammation and fever to combat foreign invaders like viruses. Contrarily, IL-1’s antagonist, Interleukin-1 receptor antagonist (IL-1Ra), serves to block IL-1’s receptors, thus tempering the inflammatory response and preventing it from becoming excessive.
Immune Responses to IL-1Ra
Interestingly, some individuals’ immune systems produce antibodies against IL-1Ra, rendering it ineffective. Professor Christoph Kessel from the University of Münster explains that in these cases, the immune system inaccurately targets this antagonistic molecule, thereby removing it from action. This opens the floodgates for IL-1 to bind unchecked, causing rampant inflammation. The delicate balance between inflammatory responses and their inhibition is disrupted.
Deciphering the Mechanism in COVID-19
For some time, researchers have understood the implications of IL-1Ra in severe cases of COVID-19. However, the specific alterations occurring at the molecular level within IL-1Ra were previously obscure. Recent investigations, involving an interdisciplinary team, have unveiled this mechanism among critically ill COVID patients during the pandemic’s peak, published in Nature Communications. Researchers Evi Regitz and Natalie Fadle noted atypical biochemical changes at certain sites on IL-1Ra among these patients, leading to a breakdown in tolerance towards IL-1Ra. This, in turn, triggers a cascade of immune and inflammatory responses, identifying previously unknown vulnerabilities.
Insights from the NAPKON Project
A significant source of data for this study came from the German NAPKON project, a collaborative effort that centralized national research activities during the COVID-19 pandemic. Lorenz Thurner highlights that these data are invaluable, revealing that the immune system’s dysregulation appears to be a temporary effect. Over time, the levels of antibodies against IL-1Ra diminish in affected individuals.
Implications for Other Diseases
The mechanism elucidated in COVID-19 patients has broader implications, as similar hyper-phosphorylation phenomena are implicated in other diseases. In a related report published in the Annals of the Rheumatic Diseases, researchers identified comparable biochemical changes in signaling molecules linked to axial spondyloarthritis, a chronic inflammatory rheumatic condition.
Conclusion
Understanding the delicate interplay of immune responses, particularly the roles of IL-1 and IL-1Ra, is crucial in managing diseases marked by inappropriate immune reactions. As research continues, questions remain about whether COVID-19 is a catalyst for these changes or whether such responses were pre-existing in patients. Future studies are essential to unravel these complexities and enhance therapeutic strategies against both COVID-19 and related autoimmune conditions.
References
Thurner L. et al. (2026) “Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms,” DOI: 10.1038/s41467-026-73316-5
Abdi Z. et al. (2026) “Proinflammatory autoantibodies enhancing tumor necrosis factor and RANKL signaling in axial spondyloarthritis associate with hyperphosphorylated progranulin and osteoprotegerin,” DOI: 10.1016/j.ard.2026.04.008
